Why the study?
Does Ticlopidine prevent post-operative thrombosis compared to acenocoumarol in patients undergoing suprapubic prostatectomy?
Does Ticlopidine prevent post-operative thrombosis compared to acenocoumarol in patients undergoing suprapubic prostatectomy?
Ticlopidine appears to offer comparable protection against deep venous thrombosis as acenocoumarol after suprapubic prostatectomy, with acceptable bleeding risk.
Ticlopidine provides comparable DVT prophylaxis to acenocoumarol after prostatectomy; extends options for patients needing alternatives to vitamin K antagonists.
In order to study in its protective effect against post-operative thrombosis, Ticlopidine was administered to one out of two randomized groups of patients undergoing suprapubic prostatectomy. Bleeding time, platelet function, and haematological parameters were followed. Blood loss during operation and post-operatively were estimated, transfusions required and subjective tolerance were recorded. Among twenty-six evaluated patients receiving Ticlopidine, positive leg scans were found in four, whereas among twenty patients treated with acenocoumarol post-operatively, positive leg scans were found in seven patients. The difference is not statistically significant, thus Ticlopidine appears to offer a protection against deep venous thrombosis comparable to that of acenocoumarol. A score is introduced for comparison of the results of aggregation tests. Platelet aggregability diminished during the use of the drug, but the adhesiveness was not influenced by Ticlopidine. The bleeding time was prolonged in both groups studied. Ticlopidine did not raise per-operative blood loss and caused only slightly more haematuria post-operatively. The subjective tolerance was good.
No takes yet. Share an insight, caveat, or question.
E.J.P. Brommer (1981) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: